Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years

Condition:   COVID-19 Interventions:   Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule;   Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule;   Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule;   Biological: Placebo on a 0- a nd 28-day schedule Sponsors:   Chinese Academy of Medical Sciences;   West China Second University Hospital;   Yunnan Center for Disease Control and Prevention Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials